New Psychoactive Substances: Risks and Challenges
DOI:
https://doi.org/10.17140/TFMOJ-2-117Keywords:
New psychoactive substances (NPS), Centre for Drugs and Drug Addiction (EMCDDA)Abstract
New psychoactive substances (NPS) have emerged in the last few years in response to market trends and legislative control. Only in the EU, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) reported in its European Drug Report 2016 the monitoring of more than 560 novel substances, of which 380 (70%) were detected in the past 5 years.
References
European Drug Report 2016: Trends and Developments. (EMCDDA). 2016.
Helander A, Bäckberg M. New psychoactive substances (NPS) – the Hydra monster of recreational drugs. Clin Toxicol (Phila). 2017; 55:1: 1-3. doi: 10.1080/15563650.2016.1217003
Baumann MH, Volkow ND. Neuropsychopharmacology. 2016; 41: 663-665. doi: 10.1038/npp.2015.260
Yapa S, Drummer OH. Prevalence of new psychoactive sub-stances in Victorian fatally-injured drivers. Aust J Forensic Sci. 2016; 48(2): 230-243. doi: 10.1080/00450618.2015.1050066
Lobo J, Chassaigne H, Holland M, et al. Systematic ana-lytical characterization of new psychoactive substances: A case study. Forensic Sci Int. 2016; 265: 107-115. doi: 10.1016/j. forsciint.2016.01.024
Gerostamoulos D, Elliott S, Walls HC. To measure or not to measure? That is the NPS question. J Anal Toxicol. 2016; 40: 318-320. doi: 10.1093/jat/bkw013
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Toxicology and Forensic Medicine (TFM) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
